Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed

Trial Profile

Phase II trial of anetumab ravtansine (BAY 94-9343) in patients with advanced or metastatic malignant pleural mesothelioma (MPM) overexpressing mesothelin after first line treatment with platinum in combination with pemetrexed

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Malignant-mesothelioma
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 12 Mar 2016 There is one more trial (CTP 263551) similar to this trial.Trial data reported in CTP 263551 reports about BAY 94-9343 as primary drug and Vinorelbine as active comparator, as reported per EudraCT and CT.gov sources. But UKCRN 19468 record does not mention about use of "Vinorelbine" in trial.So as of now I have created this record. In future, if any amendment in UKCRN record (269009) suggests use of "Vinorelbine" this CTP(269009) need to be merged with CTP (263551).
    • 12 Mar 2016 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top